Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 3:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 6,121 matching trials from the live ClinicalTrials.gov search.
Terminated No phase listed Observational Accepts healthy volunteers Results available

Fatty Acid Ethyl Esters in Meconium of Infants of Diabetic Mothers: a Pilot Trial

NCT02308735
Conditions
Infants of Diabetic Mothers
Interventions
N/A - No intervention
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
Up to 45 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
Diabetes Type 2
Interventions
Vitamin E, Vitamin C
Dietary Supplement
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Depression, Type 2 Diabetes Mellitus
Interventions
Education, encouragement, card sort, Education, encouragement
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Diabetes Mellitus, Type 2
Interventions
I-START, Standard Insulin Administration Education
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Infections, Meningococcal
Interventions
GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix), GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix), Infanrix®, ActHIB®, Pediarix®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,558 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
56
States / cities
Birmingham, Alabama • Dothan, Alabama • Benton, Arkansas + 50 more
Conditions
Diabetic Foot Ulcer, Diabetic Neuropathy, Type 2 Diabetes
Interventions
Diabetic Foot Ulcer Biopsy, Survey, Comprehensive Neuropathy Assessment, Wound Photography
Procedure · Other
Lead sponsor
Winthrop University Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Mineola, New York
Conditions
Diabetes (DM)
Interventions
Food is medicine
Dietary Supplement
Lead sponsor
Public Health Institute Center for Wellness and Nutrition
Other
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Stockton, California
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of Simvastatin and Albiglutide

NCT01147692
Conditions
Diabetes Mellitus, Type 2
Interventions
simvastatin plus albiglutide
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Conditions
Heart Diseases, Diabetes Mellitus, Type 2, Pre-diabetes, Hypertension, Hyperlipidemias
Interventions
Cardiovascular Risk Homeless Support
Behavioral
Lead sponsor
Katherine Vickery
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Type 2 Diabetes Mellitus
Interventions
MB07803, Placebo
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
25
States / cities
Los Angeles, California • Walnut Creek, California • Miami, Florida + 20 more
Completed No phase listed Observational Accepts healthy volunteers

Platelet PAR-1 Activation in Health and Diabetes

NCT04280549
Conditions
Type 2 Diabetes, Healthy
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Diabetes Mellitus, Type 2
Interventions
Positive Outcomes for Women
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Urinary Tract Infections, Kidney Stone
Interventions
None - observational
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
5
States / cities
Phoenix, Arizona • San Diego, California • Boston, Massachusetts + 2 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Complementary and Alternative Medicine for Urological Symptoms(CAMUS)

NCT00603304
Conditions
Urological
Interventions
Saw Palmetto - first 24 weeks, Placebo - first 24 weeks, Saw Palmetto - weeks 24 - 48, Placebo - weeks 24 - 48, Saw Palmetto - weeks 48 - 72, Placebo - weeks 48 - 72
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
45 Years and older · Male only
Enrollment
369 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
10
States / cities
Oakland, California • Aurora, Colorado • New Haven, Connecticut + 6 more
Active, not recruiting Not applicable Interventional

Strategies to Improve Well-Being and Diabetes Management

NCT06348238
Conditions
Diabetes Mellitus, Type 2
Interventions
Self-Affirmation
Behavioral
Lead sponsor
Elizabeth Scharnetzki
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Westbrook, Maine
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of HIIT vs. TRE on Type 2 Diabetes Risk

NCT07215533
Conditions
Obesity and Type 2 Diabetes, Metabolic Diseases, High-intensity Interval Training, Time-restricted Eating
Interventions
High-intensity interval training, Time-restricted eating
Behavioral
Lead sponsor
Syracuse University
Other
Eligibility
14 Years to 30 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Syracuse, New York
Conditions
Type 2 Diabetes
Interventions
DIO-902, DIO-902 placebo
Drug
Lead sponsor
DiObex
Industry
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Muscle Shoals, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 9 more
Conditions
Acute Myeloid Leukemia
Interventions
Aerobic Exercise, Resistance Training, Biospecimen Collection, Electronic Health Record Review, Survey Administration, Interview
Other · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Completed Not applicable Interventional Results available

Fuzzy Logic Automated Insulin Regulation

NCT03040414
Conditions
Type 1 Diabetes Mellitus
Interventions
MedtronicMinimed 670G 3.0 hybrid closed loop system, Medtronic Minimed 670G 4.0 AHCL with Guardian Sensor (3) continuous glucose monitoring sensor.
Device
Lead sponsor
HealthPartners Institute
Other
Eligibility
14 Years to 30 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
New Haven, Connecticut • Gainesville, Florida • Boston, Massachusetts + 1 more
Conditions
Poliomyelitis, Diphtheria, Haemophilus Influenzae Type b, Tetanus, Acellular Pertussis, Hepatitis B
Interventions
Infanrix hexa, Pediarix, ActHIB, Pentacel, Engerix-B, Infanrix, Hiberix, Prevnar13, Rotarix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
585 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
43
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 38 more
Recruiting Not applicable Interventional Accepts healthy volunteers

Mobile App Logging for Diabetes in Pregnancy

NCT06005987
Conditions
Gestational Diabetes Mellitus in Pregnancy, Type 2 Diabetes
Interventions
OneTouch Reveal application
Behavioral
Lead sponsor
Carolyn Zahler-Miller
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Conditions
Diabetes Mellitus
Interventions
AC2993 (exenatide), daclizumab (immunosuppressive)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 3 Interventional Results available

Study of Rivoglitazone in Type 2 Diabetes Mellitus

NCT00484198
Conditions
Type 2 Diabetes Mellitus
Interventions
Pioglitazone, Placebo, Rivoglitazone
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,912 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
70
States / cities
Anniston, Alabama • Birmingham, Alabama • Hoover, Alabama + 67 more
Conditions
Multiple Myeloma
Interventions
Modakafusp alfa, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
14
States / cities
Sacramento, California • San Diego, California • Iowa City, Iowa + 8 more